ScholarX: KIM, SEUNG TAE

Detailed Information

KIM, SEUNG TAE (김승태)

Medicine (Medicine)

Research Area

Tel 02-3410-0297
Homepage

ResearcherID ORCiD Scopus Google Scholar ID ResearchGate

Keyword

Gastric cancer:20||gastric cancer:17||Chemotherapy:8||Colorectal cancer:8||2:7||Stomach neoplasms:6||immunotherapy:6||chemotherapy:6||Radiotherapy:6||Prognosis:6||nextgeneration sequencing:6||3:6||Biliary tract cancer:6||biomarker:6||prognosis:5||Pembrolizumab:5||HER2:5||Recurrence:4||Biomarker:4||KRAS:4||tumor mutational burden:4||PDL1:4||ramucirumab:3||biliary tract cancer:3||melanoma:3||MET:3||colorectal cancer:3||paclitaxel:3||ERBB2:3||Simvastatin:3||Capecitabine:3||pembrolizumab:3||Bevacizumab:3||radiotherapy:3||NGS:3||Colorectal neoplasms:3||immune checkpoint inhibitor:3||Quality of life:3||Advanced gastric cancer (AGC):3||Adjuvant:2||1700:2||6:2||Heterogeneity:2||5:2||Aflibercept:2||Concurrent chemoradiotherapy:2||Target:2||Immune checkpoint inhibitor:2||programmed deathligand 1:2||Immunohistochemistry:2||Everolimus:2||nivolumab:2||3809233482:2||Trastuzumab:2||PD1:2||bevacizumab:2||4:2||genomics:2||refractory cancer:2||1:2||PIK3CA mutation:2||CDK4/6 inhibitor:2||KRAS mutation:2||Colorectal cancer (CRC):2||Wholeexome sequencing:2||Regorafenib:2||secondline:2||Next generation sequencing:2||liquid biopsy:2||immune checkpoint inhibition:2||sirolimus:2||cMET:2||Ramucirumab:2||stomach neoplasm:2||RAF inhibitor:2||Nextgeneration sequencing:2||PET:2||Nivolumab:2||16:2||ATM:2||advanced gastric cancer:2||MerTK:2||Biomarkers:2||Sarcopenia:2||RICTOR:2||Stomach neoplasm:2||Melanoma:2||pancreatic cancer:2||Induced hyperthermia:1||Initial dose:1||Interview study:1||Irinotecan:1||Ki67 index:1||LAG3:1||LRP1B:1||Lanreotide:1||Leptomeningeal metastasis:1||Liver kinase B1:1||Liver metastases:1||MAP2K1 mutation:1||MEK:1||MEK inhibitor:1||MET alterations:1||MSI high:1||Machine learning:1||Maximum tolerated dose:1||Mesorectalfascia:1||Metastasis:1||Metastatic cancer:1||Metastatic colorectal cancer:1||Methylation array:1||Methylprednisolone:1||Microfluidic chip:1||Microsatellite instability:1||Microsatellite instabilityhigh:1||Minnelide:1||Molecular:1||Molecular screening:1||Molecular subtype:1||Molecular tumor board:1||Mutation:1||Neoadjuvant therapy:1||Neoadjuvant treatment:1||Neoplasm staging:1||Neoplasms:1||Neuroendocrine tumor:1||NextGeneration Sequencing:1||Nomogram:1||Octreotide:1||Oxaliplatin:1||PARP:1||PD1 inhibitor:1||PIK3CA amplification/mutation:1||PIK3CAE542K:1||PRKCI:1||PRO007:1||PTEN loss:1||PTEN mutation:1||Paclitaxel:1||Pain:1||Pancreatic neuroendocrine tumor:1||Pathologic complete response:1||Patientderived cell:1||Patientderived tumor spheroids:1||Patterns of failure:1||Pemetrexed:1||Peptide receptor radionuclide therapy:1||Pharmacogenomics:1||Phase II clinical trial:1||Physical function:1||Platinum:1||Precision medicine:1||Prediction:1||Prediction model:1||Predictive marker:1||Preoperative chemoradiotherapy:1||Prognostic factor:1||Programmed Cell Death 1 Receptor:1||Programmed cell death 1:1||Programmed cell death ligand 1 expression:1||Programmed death ligand 1:1||Programmed death ligand 1 expression:1||Programmed deathligand 1:1||Qualitative research:1||RAF1 aberration:1||RANOLM:1||RET fusion:1||RNF11:1||Radiomics:1||Randomized trial:1||Rapid infusion:1||Receptor tyrosine kinase:1||Rectal cancer:1||Rectal neoplasms:1||Rehabilitation:1||Renal insufficiency:1||Residual tiny metastasis:1||Response:1||Ribonucleic acid sequencing:1||SAIT301:1||SMO:1||Salvage therapy:1||Salvage treatment:1||Sequencing:1||Serine/threonine kinase 11:1||Sidedness:1||Skin:1||Smartphone aftercare:1||Stomach cancer:1||Sunitinib:1||TAS102:1||TAS102 plus bevacizumab:1||TCGA molecular subtype:1||TMB:1||TPK1:1||Targeted sequencing:1||Targeted therapy:1||Temozolomide:1||The effect of bevacizumab was not different between LC and RC and between MSS and the MSIH tumors:1||Therapy:1||TruSight™ Oncology 500 assay:1||Tumor:1||Tumor mutation burden (TMB):1||Vandetanib:1||Vasculardisrupting agent:1||Vismodegib:1||Wholetranscriptome sequencing:1||XELOX:1||[F18]FDG:1||adjuvant:1||adjuvant chemotherapy:1||adjuvant therapy:1||advanced biliary tract cancer:1||advanced gastric cancer (AGC):1||amplification:1||and Tumor burden:1||angiogenesis:1||antiangiogenesis:1||ataxia telangiectasia and Rad3 related protein (ATR):1||biliary tract neoplasms:1||cerbB2 gene:1||cancer:1||ceralasertib:1||cfDNA:1||checkpoint inhibitor:1||circulating tumor DNA:1||cisplatin:1||claudin 18.2:1||clinical trials, phase II as topic:1||coamplification:1||colon cancer:1||colorectal cancer (CRC):1||combined positive score:1||cutoff points:1||c‑KIT mutation:1||dRecurrence:1||dabrafenib/trametinib:1||durvalumab:1||efficacy:1||endoscopy:1||epigenetic alternate promoter:1||epithelial–mesenchymal transition (EMT):1||erlotinib:1||etoposide:1||firstline therapy:1||firstline treatment:1||fusion:1||gastrectomy:1||gastroenteropancreatic neuroendocrine neoplasm (GEPNEN):1||gastroenteropancreatic neuroendocrine carcinoma (GEPNEC)s:1||gastroenteropancreatic neuroendocrine neoplasm:1||gastrointestinal cancer:1||gastrointestinal neoplasms:1||gastrointestinal tract:1||gene fusions:1||gene signature:1||genetic diagnosis:1||genome instability:1||genomic:1||hepatocyte growth factor:1||highthroughput drug screening:1||highthroughput screening (HTS):1||human epidermal growth factor receptor 2:1||human epidermal growth factor receptor 2 (HER2):1||imatinib:1||immune cell fraction:1||immune check point inhibitor:1||immune checkpoint blockade:1||immune infiltrates:1||immune resistance:1||immunohistochemistry:1||inflammation:1||intratumoral heterogeneity:1||landscape:1||leptomeningeal metastases:1||leukocyte count:1||liposomal irinotecan:1||mHealth:1||mTORC1/2:1||mammalian target of rapamycin inhibitor (mTOR inhibitor):1||margetuximab:1||mesenchymal:1||metastatic colorectal cancer:1||metastatic gastroesophageal adenocarcinoma:1||metastatic solid tumor:1||microsatellite instability:1||mismatch repair deficiency (dMMR):1||molecular targeted therapy:1||neoadjuvant therapy:1||neuroendocrine carcinoma:1||neuroendocrine carcinoma (NEC):1||neuroendocrine tumor:1||neuroendocrine tumor (NET):1||nextgeneration genome sequencing:1||nextgeneration sequencing (NGS):1||oncogene:1||oncology:1||overall survival:1||overall survival analysis:1||pancreatic adenocarcinoma:1||pancreaticobiliary tract cancer:1||panel sequencing:1||pathologic differentiation:1||pathology:1||pathway:1||patientderived cell (PDC):1||patientderived cells:1||patientderived tumor cell:1||patientderived tumor cells:1||pemetrexed:1||pharmacodynamics:1||pharmacokinetics:1||phase I:1||platelet count:1||precision:1||precision medicine:1||primary tumor site:1||prognostic factor:1||programmed cell death 1 receptor:1||programmed cell deathligand 1 (PDL1):1||programmed deathligand 1 (PDL1):1||programmed deathligand 1 expression:1||progressionfree survival:1||radiation therapy:1||radiosensitivity:1||realworld evidence:1||recurrence:1||regorafenib:1||response rate:1||retifanlimab:1||safety:1||salvage treatment:1||sarcopenia:1||scoring model:1||secondline treatment:1||selumetinib:1||singlenucleotide variants:1||solid cancer:1||sorafenib:1||stomach neoplasms:1||subtypes:1||survival:1||target therapy:1||targeted therapy:1||trastuzumab:1||tumor heterogeneity:1||tumor mutation burden:1||tumor purity:1||twodrug combination:1||vitamin:1||young:1||zolbetuximab:1||130540543122772683:1||1589:1||1704:1||239:1||2614921992823:1||2614922769:1||261492353223705109:1||261566324895429243:1||2813189499:1||283237255:1||30min infusion:1||303:1||32822062497:1||32822062798:1||3282330646143760:1||3809218438:1||3809229068:1||3D culture:1||8:1||AZD2014:1||Adjuvant therapy:1||Advanced gastric cancer:1||Advanced solid cancer:1||Adverse event:1||And vascular endothelial growth factor receptor 2 (VEGFR2):1||Angiogenesis:1||Angiogenesis signature:1||Ataxia telangiectasia mutated (ATM):1||BRAF V600–mutant advanced melanoma:1||BRAF mutation:1||BRAF/EGFR inhibitor:1||Biliary tract neoplasm:1||CD8:1||CDH1:1||CKD516:1||CT:1||CXCL13:1||Cancer:1||Cancer chemotherapy:1||Cancer immunotherapy:1||Cerebrospinal fluid:1||Cerebrospinal fluid (CSF):1||Checkpoint inhibitor:1||Circulating tumor cells:1||Circulating tumor cells (CTCs):1||Clinical trials:1||Colorectal liver metastasis:1||Computed tomography:1||DLL4:1||DNA:1||DNA checkpoint gene mutation:1||DNA damage:1||Dexamethasone:1||Digital image analysis:1||Disappearing metastasis:1||Elderly:1||Emesis:1||Epidermal growth factor ointment:1||Epidermal growth factor receptor:1||Epithelialmesenchymal transition:1||Epstein–Barr virus:1||ErbB2 receptor:1||Ethnic groups:1||FGFR2:1||FGFR2 amplification:1||FGFR2amplified:1||FOXP3:1||Family history:1||Fibroblast growth factor receptor 2:1||Firstline chemotherapy:1||Fluorescence in situ hybridization:1||GEPNEC:1||Gadoxetic acidenhanced MRI:1||Gastric carcinoma:1||Gastroenteropancreatic neuroendocrine carcinoma:1||Gastroesophageal junction adenocarcinoma:1||Gefitinib:1||Genomic:1||Genomic alterations:1||Glomerular filtration rate:1||Guardant360:1||HER2 expression:1||HRD:1||Hedgehog pathway:1||Hepatocyte growth factor:1||Hiccup:1||Histology:1||

STATISTICS: Total View:; Daily View:

RSS_1.0 RSS_2.0 ATOM_1.0

(03063) 25-2, SUNGKYUNKWAN-RO, JONGNO-GU, SEOUL, KOREA samsunglib@skku.edu

Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.

Detailed Information

Keyword

BROWSE